cycloheptatrienylium; chloride

• 分子结构分类: 有机化合物 - 碳氢化合物衍生物
• 英文名称: cycloheptatrienylium; chloride
• 英文别名: tropylium chloride；Cycloheptatrienylium; Chlorid；Cyclohepta-1,3,5-triene;chloride
• 化学式: C₇H₇*Cl
• 分子量: 126.586
• InChiKey: RZTXGZWUIFYJNC-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -1.03
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  cycloheptatrienylium; chloride 、 原阿片碱 生成 alkaline earth salt of/the/ methylsulfuric acid 、 alkaline earth salt of/the/ methylsulfuric acid
  参考文献：
  名称：

  Long-term treatment of focal segmental glomerulosclerosis in children with cyclosporine given as a single daily dose

  摘要：

  Cyclosporine (CsA) has been successfully used for treatment of children with focal segmental glomerulosclerosis (FSGS) and nephrotic syndrome (NS) for the last decade. Response rates of 50% to 100% have been reported using twice-daily dosing of 5 to 32 mg/kg/d, achieving trough blood levels of 70 to 500 ng/mL. Treatment has been associated with a high incidence of side effects, including nephrotoxicity, hypertension, gingival hyperplasia, and hirsutism. To determine whether once-daily low-dose CsA could minimize side effects and still induce remission, 21 children with biopsy-proven FSGS and NS, each treated with CsA, 4.6 +/- 0.8 mg/kg/d, with no predetermined target trough blood levels, were studied. Eleven of 21 children (52%) attained complete remission and 5 of 21 children (24%) attained partial remission, for a total response rate of 76%. Mean time to response was 2.8 +/- 0.8 months, and mean duration of therapy was 20.6 +/- 13.7 months. CsA dosage was tapered or stopped in 9 responders; 3 of these patients maintained remission at last follow-up 6 to 13 months later, and 6 patients relapsed at 1.5 to 18.7 months (mean, 8.7 months). Five of these 6 patients responded again when CsA therapy was restarted or the dosage was increased. Twelve of 16 responders were still being administered CsA at last follow-up 11 to 60 months (mean, 24.6 months) later. Five of 21 patients (24%) had no response to CsA during 2 to 27 months of therapy; 4 of these 5 patients developed end-stage renal disease after CsA therapy was stopped. Side effects of CsA therapy were minimal: 1 patient each developed new-onset hypertension or gingival hyperplasia, and no patient had hirsutism or nephrotoxicity. Single daily low-dose CsA appears to be effective for long-term treatment of children with FSGS and NS, with fewer side effects than twice-daily dosing. (C) 2001 by the National Kidney Foundation, Inc.

  DOI：

  10.1053/ajkd.2001.27692
• 作为产物：
  描述：

  环庚三烯 在 二氧化硫 、 三苯基氯甲烷 作用下， 生成 cycloheptatrienylium; chloride
  参考文献：
  名称：

  SYNTHESIS OF TROPENIUM (CYCLOHEPTATRIENYLIUM) SALTS BY HYDRIDE EXCHANGE¹

  摘要：

  DOI：

  10.1021/ja01573a084

文献信息

• 252. Tropylium salts. Part II. Valid and invalid preparations of tropylium chloride: an unusual tropylium–phosphorus chloride complex
  作者：D. Bryce-Smith、N. A. Perkins

  DOI：10.1039/jr9620001339

  日期：——
• Palou, Josefina; Robinson, Peter M.; Watt, C. Ian F., Journal of the Chemical Society. Perkin transactions II, 1995, # 11, p. 1999 - 2004
  作者：Palou, Josefina、Robinson, Peter M.、Watt, C. Ian F.

  DOI：——

  日期：——
• ETHYLENE POLYMER, CATALYST FOR PRODUCTION OF ETHYLENE POLYMER, AND PROCESS FOR PRODUCTION OF ETHYLENE POLYMER
  申请人：Tosoh Corporation

  公开号：EP1964860B1

  公开（公告）日：2017-07-05
• ETHYLENE POLYMER, CATALYST FOR ETHYLENE POLYMER PRODUCTION, AND METHOD FOR PRODUCING ETHYLENE POLYMER
  申请人：Yamada Satoru

  公开号：US20090137755A1

  公开（公告）日：2009-05-28

  An object of the present invention relates to provide an ethylene polymer having excellent mechanical strength and excellent molding processability in a wide molding processing temperature range. The invention relates to use an ethylene polymer comprising a repeating unit derived from ethylene, or a repeating unit derived from ethylene and a repeating unit derived from a C 3-8 α-olefin, the ethylene polymer being satisfied with the following (A) to (F). (A) Density (d(kg/m 3 )) is from 910 to 970, (B) MFR(g/10 min)) is from 0.01 to 50, (C) terminal vinyl number is 0.2 or less per 1,000 carbon atoms, (D) melt strength (MS 160 (mN)) measured at 160° C. and MFR are satisfied with MS 160 >90−130×log(MFR), (E) melt strength (MS 190 (mN)) measured at 190° C. and MS 160 are satisfied with MS 160 /MS 190 <1.8, and (F) fluidized activation energy (E a (kJ/mol)) and d are satisfied with 127−0.107 d
• ETHYLENE-alpha-OLEFIN COPOLYMER AND MOLDED ARTICLE
  申请人：Nozue Yoshinobu

  公开号：US20130005930A1

  公开（公告）日：2013-01-03

  An ethylene-α-olefin copolymer, wherein the ethylene-α-olefin copolymer has a density of 860 to 950 kg/m 3 and a melt flow rate of 0.01 to 100 g/10 min, wherein in a molecular weight curve measured by gel permeation chromatography, the molecular weight of the copolymer providing the highest peak exists within the range of 10,000 to 20,000, wherein the height of the peak at a molecular weight of 177,000 is 5 to 30% where the height of the highest peak is 100%, wherein a characteristic relaxation time of the copolymer satisfies a relation represented by formula (1), and wherein the ethylene-α-olefin copolymer exhibits more than one melt peak observed by a differential scanning calorimeter. 40.2×MFR −0.606 <τ<71.8×MFR −0.175 (1)